N30 Pharma is focused on developing innovative first-in-class therapeutics, based on novel mechanistic approaches, with established proof of concept. These agents are designed to provide significant advances over current treatments for respiratory, cardiovascular, and gastrointestinal disease and associated inflammatory conditions.
Our current portfolio consists initially of two lead efforts that address acute and chronic respiratory disease. N30 Pharma is developing these first-in-class therapeutics to address the significant limitations of existing therapies in the worldwide multi-billion dollar respiratory disease market.
Our proprietary programs are focused on asthma, COPD, cardiovascular diseases and inflammation and offer a broad and diverse platform for which the Company has full rights.
These N30 Pharma drug candidates have multiple modes of administration including injectable, oral, inhalation, and topical.